Approval · Notice of Compliance 25123 · 2021
SYLVANT: Notice of Compliance 25123
Issued January 26, 2021
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 25123
- Date
- January 26, 2021
- Company
- Eusa Pharma (Uk) Limited
- Product type
- Biologic
- Submission
- New Drug Submission (NDS)
- Submission class
- Admin
- Reason
- Administrative - change in product ownership
Products in this notice
Medicinal ingredients
- SILTUXIMAB 100 MG per VIAL
- SILTUXIMAB 400 MG per VIAL